PH12020551313B1 - Ophthalmic composition comprising diquafosol and cationic polymer - Google Patents

Ophthalmic composition comprising diquafosol and cationic polymer

Info

Publication number
PH12020551313B1
PH12020551313B1 PH1/2020/551313A PH12020551313A PH12020551313B1 PH 12020551313 B1 PH12020551313 B1 PH 12020551313B1 PH 12020551313 A PH12020551313 A PH 12020551313A PH 12020551313 B1 PH12020551313 B1 PH 12020551313B1
Authority
PH
Philippines
Prior art keywords
cationic
copolymer
hydrolyzed
diquafosol
ophthalmic composition
Prior art date
Application number
PH1/2020/551313A
Other languages
English (en)
Other versions
PH12020551313A1 (en
Inventor
Hiroyuki Asada
Kenichi Endo
Asuka Kamimura
Yusuke Momokawa
Kenji Morishima
Kyohei Takahashi
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of PH12020551313A1 publication Critical patent/PH12020551313A1/en
Publication of PH12020551313B1 publication Critical patent/PH12020551313B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
PH1/2020/551313A 2018-02-28 2019-02-27 Ophthalmic composition comprising diquafosol and cationic polymer PH12020551313B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018035578 2018-02-28
PCT/JP2019/007542 WO2019168023A1 (ja) 2018-02-28 2019-02-27 ジクアホソルおよびカチオン性ポリマーを含有する眼科用組成物

Publications (2)

Publication Number Publication Date
PH12020551313A1 PH12020551313A1 (en) 2021-09-06
PH12020551313B1 true PH12020551313B1 (en) 2024-02-28

Family

ID=67806273

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2020/551313A PH12020551313B1 (en) 2018-02-28 2019-02-27 Ophthalmic composition comprising diquafosol and cationic polymer

Country Status (14)

Country Link
US (1) US20210000844A1 (cg-RX-API-DMAC10.html)
EP (1) EP3760207A4 (cg-RX-API-DMAC10.html)
JP (5) JP6716800B2 (cg-RX-API-DMAC10.html)
KR (3) KR20250053220A (cg-RX-API-DMAC10.html)
CN (2) CN117137866A (cg-RX-API-DMAC10.html)
BR (1) BR112020017661A2 (cg-RX-API-DMAC10.html)
CA (1) CA3091700A1 (cg-RX-API-DMAC10.html)
EA (1) EA202092030A1 (cg-RX-API-DMAC10.html)
MX (2) MX2020008925A (cg-RX-API-DMAC10.html)
PH (1) PH12020551313B1 (cg-RX-API-DMAC10.html)
SG (1) SG11202007977RA (cg-RX-API-DMAC10.html)
TW (4) TW202600146A (cg-RX-API-DMAC10.html)
UA (1) UA129517C2 (cg-RX-API-DMAC10.html)
WO (1) WO2019168023A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202007977RA (en) * 2018-02-28 2020-09-29 Santen Pharmaceutical Co Ltd Ophthalmic composition comprising diquafosol and cationic polymer
WO2020175525A1 (ja) * 2019-02-27 2020-09-03 参天製薬株式会社 ジクアホソルまたはその塩、ビニル系高分子およびセルロース系高分子を含有する眼科用組成物
JP6966667B2 (ja) * 2019-08-27 2021-11-17 参天製薬株式会社 ジクアホソルまたはその塩、およびポリビニルピロリドンを含有する水性眼科用組成物
KR102365008B1 (ko) * 2020-06-23 2022-02-23 주식회사태준제약 디쿠아포솔을 포함하는 점안 조성물
JP7230169B2 (ja) * 2020-12-25 2023-02-28 参天製薬株式会社 ジクアホソルまたはその塩、銀塩およびイオン性等張化剤を含有する水性点眼液
CN113712910A (zh) * 2021-08-05 2021-11-30 广州市桐晖药业有限公司 一种滴眼液及其制备方法
WO2023054669A1 (ja) * 2021-09-30 2023-04-06 ロート製薬株式会社 眼科組成物
KR102794468B1 (ko) 2022-04-04 2025-04-14 서울대학교산학협력단 감미 억제용 조성물 및 식품의 감미 억제 방법
JP2024043685A (ja) * 2022-09-20 2024-04-02 参天製薬株式会社 ジクアホソルまたはその塩を含有する眼科用組成物のpHの低下を抑制する方法
KR20250038935A (ko) * 2023-09-13 2025-03-20 루다큐어 주식회사 8-옥소-2'-데옥시구아노신 또는 이의 약학적으로 허용가능한 염을 포함하는 수용액 형태의 점안제
KR20250160050A (ko) 2024-05-03 2025-11-11 삼천당제약주식회사 물리화학적 특성이 개선된 안구건조증 예방 또는 치료용 약학 조성물
CN119970633A (zh) * 2025-03-26 2025-05-13 苏州乐珠制药有限公司 一种地夸磷索钠滴眼液及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01294620A (ja) 1988-05-19 1989-11-28 Kissei Pharmaceut Co Ltd 水溶液製剤およびその製造方法
US5358706A (en) * 1992-09-30 1994-10-25 Union Carbide Chemicals & Plastics Technology Corporation Muco-adhesive polymers
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
JP3155689B2 (ja) * 1995-08-10 2001-04-16 昭和薬品化工株式会社 消炎点眼剤
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
CA2295515C (en) 1997-07-25 2006-03-14 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5'-tetraphosphate) and salts thereof
JP2001294620A (ja) 2000-04-11 2001-10-23 Showa Denko Kk プラスチックレンズ材料、該材料の製造方法、プラスチックレンズ用組成物、該組成物を硬化してなるプラスチックレンズ、及び該プラスチックレンズの製造方法
AU2001260643B9 (en) * 2000-05-30 2006-10-19 Merck Sharp & Dohme Corp. Ectocornea extension promoters
KR101389300B1 (ko) * 2005-02-14 2014-04-25 존슨 앤드 존슨 비젼 케어, 인코포레이티드 안과용 렌즈의 제조방법, 안과용 장치 및 콘택트 렌즈
JP4515960B2 (ja) 2005-05-19 2010-08-04 株式会社資生堂 整髪料洗浄剤及びその使用方法
KR100870104B1 (ko) * 2005-11-28 2008-11-26 주식회사 머젠스 안구건조증 치료 및 예방용 조성물
CN103191129A (zh) * 2007-10-12 2013-07-10 C.T.辨析有限公司 治疗眼睛病症的脂氧化物类化合物
MX2010009857A (es) * 2008-03-07 2010-12-07 Sun Pharma Advanced Res Co Ltd Composicion oftalmica.
AU2011350762B2 (en) * 2010-12-28 2017-04-06 Santen Pharmaceutical Co., Ltd. Ophthalmic solution containing diquafosol, method for producing same, and method for preventing formation of insoluble precipitate
MY169816A (en) * 2012-03-26 2019-05-16 Santen Pharmaceutical Co Ltd Ophthalmic solution comprising diquafosol
EP3139903B1 (en) * 2014-05-07 2019-07-03 Croma-Pharma Gesellschaft m.b.H. Aqueous ophthalmic solution and method for treating dry eye syndrome
WO2015190483A1 (ja) * 2014-06-10 2015-12-17 ロート製薬株式会社 眼科用水性組成物
EA034517B1 (ru) * 2014-12-25 2020-02-17 Сантен Фармасьютикал Ко., Лтд. Водный офтальмологический раствор
KR101587385B1 (ko) 2015-07-29 2016-01-21 국제약품공업주식회사 사이클로스포린 함유 무자극성의 안약조성물 및 편리한 제조방법
JP2017043607A (ja) * 2015-08-24 2017-03-02 参天製薬株式会社 眼科用フィルム製剤
DK3266446T3 (en) * 2016-07-07 2019-02-11 Salvat Lab Sa Eye preparation comprising castor oil and medium chain triglyceride
CN106772747B (zh) * 2016-12-26 2022-10-18 深圳市光科全息技术有限公司 一种光学膜及其制作方法
BR112019018368B1 (pt) * 2017-04-25 2021-03-02 Wakamoto Pharmaceutical Co.,Ltd composição oftálmica aquosa
JP6582029B2 (ja) * 2017-10-03 2019-09-25 株式会社メニコン 眼科用組成液及びその使用方法
SG11202007977RA (en) * 2018-02-28 2020-09-29 Santen Pharmaceutical Co Ltd Ophthalmic composition comprising diquafosol and cationic polymer
CN108853016A (zh) * 2018-09-26 2018-11-23 广州大光制药有限公司 一种地夸磷索钠滴眼液及其制备方法
WO2020175525A1 (ja) * 2019-02-27 2020-09-03 参天製薬株式会社 ジクアホソルまたはその塩、ビニル系高分子およびセルロース系高分子を含有する眼科用組成物
JP6966667B2 (ja) * 2019-08-27 2021-11-17 参天製薬株式会社 ジクアホソルまたはその塩、およびポリビニルピロリドンを含有する水性眼科用組成物

Also Published As

Publication number Publication date
KR20220163519A (ko) 2022-12-09
CA3091700A1 (en) 2019-09-06
US20210000844A1 (en) 2021-01-07
JP2020138980A (ja) 2020-09-03
SG11202007977RA (en) 2020-09-29
JPWO2019168023A1 (ja) 2020-05-28
JP7796782B2 (ja) 2026-01-09
JP6716800B2 (ja) 2020-07-01
TWI781296B (zh) 2022-10-21
EA202092030A1 (ru) 2020-11-16
TW202423451A (zh) 2024-06-16
MX2020008925A (es) 2020-10-01
JP2026034664A (ja) 2026-02-27
UA129517C2 (uk) 2025-05-21
TWI833406B (zh) 2024-02-21
EP3760207A1 (en) 2021-01-06
CN111757742A (zh) 2020-10-09
MX2022014791A (es) 2023-01-16
TWI898399B (zh) 2025-09-21
TW202600146A (zh) 2026-01-01
JP7297718B2 (ja) 2023-06-26
TW202000212A (zh) 2020-01-01
JP2024045506A (ja) 2024-04-02
CN111757742B (zh) 2023-09-26
KR102796051B1 (ko) 2025-04-14
KR20200127002A (ko) 2020-11-09
PH12020551313A1 (en) 2021-09-06
JP7472202B2 (ja) 2024-04-22
TW202306572A (zh) 2023-02-16
BR112020017661A2 (pt) 2020-12-22
WO2019168023A1 (ja) 2019-09-06
CN117137866A (zh) 2023-12-01
KR102472773B1 (ko) 2022-11-30
JP2022136152A (ja) 2022-09-15
EP3760207A4 (en) 2023-10-04
KR20250053220A (ko) 2025-04-21

Similar Documents

Publication Publication Date Title
MX2022014791A (es) Composicion oftalmica que comprende dicuafosol y polimero cationico.
EP4465261A3 (en) Eye tracking calibration techniques
EP4445954A3 (en) Cellular models of and therapies for ocular diseases
MX2021002100A (es) Sistemas y metodos para dimensionar e implantar valvulas cardiacas protesicas.
WO2017143239A8 (en) Systems and methods for augmented reality representations of networks
EP4446363A3 (en) Dermal fillers and applications thereof
EP3939047A4 (en) METHODS AND SYSTEMS FOR SEQUENCE CALLING
GB202202470D0 (en) Bio-ink formulations, bio-printed corneal lenticule, and applications thereof
MY199333A (en) Olefin-olefinic alcohol copolymer, and preparation method therefor
WO2019222390A8 (en) Pathogen control compositions and uses thereof
BR0205199A (pt) Polìmeros de radical livre catiÈnicos ou anfóteros, utilização dos mesmos, composição cosmética, e, processos para o tratamento de materiais de queratina e para a realização de penteados
BR112018072343A2 (pt) método de determinação de um filtro para uma lente oftálmica em função de uma grandeza representativa de uma sensibilidade dinâmica do olho de um portador a uma variação de um fluxo luminoso
WO2004004757A8 (en) Treatment for eye disorder
JP2017526983A (ja) 多機能インサートシャーシクリップを有するアイウェア
EP3890623A4 (en) SOFT TISSUE IMPLANT SYSTEMS, INSTRUMENTS AND RELATED PROCEDURES
MY190011A (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
EP3946408A4 (en) CHEMICAL PROTEINS AND CHEMICAL PROTEIN COMPLEXES AGAINST FMS-LIKE TYROSINE KINASE 3 (FLT3)
PH12019501869A1 (en) Virtual reality head-mounted apparatus
PH12019500934A1 (en) Opthalmic solution comprising epinastine
MX2022003324A (es) Insertos oculares de hidrogel blando envasados en humedo.
EP3700478A4 (en) SYSTEMS AND PROCEDURES FOR CORNEAL IMPLANTS
EP4043163A4 (en) ROBOT SURGICAL SYSTEM, EXTERNAL FORCE MEASUREMENT DEVICE AND PROGRAM
EP3741241A3 (en) Improvement to facemasks
ATE482003T1 (de) Kosmetische zubereitung mit wachskomponente, filmbildner und gelkomponente
NO20025251L (no) Materiale for belegning av pölser og hard ost